Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bayer, Onyx Begin Enrollment in STORM Trial | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Bayer, Onyx Begin Enrollment in STORM Trial

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals began enrolling patients in the STORM (Sorafenib as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma) trial. The randomized, double-blind, placebo-controlled Phase III study is evaluating Nexavar (sorafenib) tablets as adjuvant treatment for patients with hepatocellular carcinoma (HCC), or primary liver cancer.
   
“Nexavar is the only systemic therapy with proven efficacy and tolerability in HCC across multiple patient populations,” said Dimitris Voliotis, M.D., vice president, Nexavar Clinical Development, Bayer HealthCare Pharmaceuticals. “Liver cancer is the third largest global cancer killer worldwide and there is a significant need for new therapies that can be used at all stages in the course of the disease to delay disease progression and prolong life.”
   
In addition, the FDA has completed a SPA for the STORM trial. An SPA is a written agreement on the design and size of a trial intended to form the basis for a new drug application.
   
The trial is expected to enroll approximately 1,100 patients and will include patients who have received surgical resection or local ablation. The study will look at whether oral Nexavar delays the time to recurrence and increases overall survival. The primary endpoint of the study is recurrence free survival. Secondary endpoints include overall survival, time to recurrence, patient-reported outcomes, plasma biomarkers, safety and tolerability.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters